AR003125A1 - Antigenos bacterianos para el diagnostico de infecciones con helicobacter pylori, una molecula de adn que lo codifica, un vector, una celula huesped,procedimiento para producir el polipeptido, composiciones para vacunas adecuadas para uso terapeutico y profilactico, el uso del polipeptido en la - Google Patents

Antigenos bacterianos para el diagnostico de infecciones con helicobacter pylori, una molecula de adn que lo codifica, un vector, una celula huesped,procedimiento para producir el polipeptido, composiciones para vacunas adecuadas para uso terapeutico y profilactico, el uso del polipeptido en la

Info

Publication number
AR003125A1
AR003125A1 ARP960102670A AR10267096A AR003125A1 AR 003125 A1 AR003125 A1 AR 003125A1 AR P960102670 A ARP960102670 A AR P960102670A AR 10267096 A AR10267096 A AR 10267096A AR 003125 A1 AR003125 A1 AR 003125A1
Authority
AR
Argentina
Prior art keywords
infections
diagnosis
helicobacter pylori
proapily
elepipetico
Prior art date
Application number
ARP960102670A
Other languages
English (en)
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9502007A external-priority patent/SE9502007D0/xx
Priority claimed from SE9601085A external-priority patent/SE9601085D0/xx
Application filed by Astra Ab filed Critical Astra Ab
Publication of AR003125A1 publication Critical patent/AR003125A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a polipéptidos de recombinación que constituyen a los antígenos expuestos en superficie de Helicobacter pylori conun peso molecular aproximado de 29 kDa. La invención además provee moléculas de ácido nucleicoq ue codifican a dichos polipéptidos, así como también vectoresy células huésped que comprenden a estas moléculas de ácido nucleico. Dichos polipéptidos de recombinación son útiles para el diagnóstico de las infeccionespor H. pylori y para lafabric ación de composiciones para vacunas que desarrollan una respuesta inmune protectora contra estas infecciones, dichascomposiciones para vacunas son adecuadas tanto para uso terapéutico como para uso profiláctico.
ARP960102670A 1995-06-01 1996-05-22 Antigenos bacterianos para el diagnostico de infecciones con helicobacter pylori, una molecula de adn que lo codifica, un vector, una celula huesped,procedimiento para producir el polipeptido, composiciones para vacunas adecuadas para uso terapeutico y profilactico, el uso del polipeptido en la AR003125A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9502007A SE9502007D0 (sv) 1995-06-01 1995-06-01 Novel polypeptides
SE9601085A SE9601085D0 (sv) 1996-03-21 1996-03-21 Novel polypeptides

Publications (1)

Publication Number Publication Date
AR003125A1 true AR003125A1 (es) 1998-07-08

Family

ID=26662316

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960102670A AR003125A1 (es) 1995-06-01 1996-05-22 Antigenos bacterianos para el diagnostico de infecciones con helicobacter pylori, una molecula de adn que lo codifica, un vector, una celula huesped,procedimiento para producir el polipeptido, composiciones para vacunas adecuadas para uso terapeutico y profilactico, el uso del polipeptido en la

Country Status (22)

Country Link
US (2) US6025164A (es)
EP (1) EP0828757A1 (es)
JP (1) JP3380559B2 (es)
KR (1) KR19990022131A (es)
CN (1) CN1191544A (es)
AR (1) AR003125A1 (es)
BR (1) BR9608627A (es)
CA (1) CA2222797A1 (es)
CZ (1) CZ357397A3 (es)
EE (1) EE9700306A (es)
HU (1) HUP9901546A3 (es)
IL (1) IL122340A0 (es)
IS (1) IS4615A (es)
MY (1) MY119003A (es)
NO (1) NO975490L (es)
NZ (1) NZ303356A (es)
PL (1) PL323741A1 (es)
RU (1) RU2195463C2 (es)
SK (1) SK155297A3 (es)
TR (1) TR199701471T1 (es)
TW (1) TW570925B (es)
WO (1) WO1996038475A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2682122B1 (fr) * 1991-10-03 1995-06-09 Pasteur Institut Nouveaux genes d'helicobacter pylori. leur utilisation pour la preparation de souches recombinantes de h. pylori.
JPH08509873A (ja) 1993-05-19 1996-10-22 アンスティテュ・パストゥール ヘリコバクター感染に対する免疫組成物、該組成物に用いられるポリペプチドおよび該ポリペプチドをコードする核酸配列
US6258359B1 (en) 1993-05-19 2001-07-10 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
US6406703B1 (en) 1993-07-27 2002-06-18 Csl Limited Treatment of H. pylori associated gastroduodenal disease
KR100333113B1 (ko) * 1993-07-27 2002-11-27 시에스엘 리미티드 헬리코박터피롤리관련위십이지장질환의치료방법
AUPM612494A0 (en) * 1994-06-08 1994-06-30 Csl Limited Treatment or prevention of helicobacter infection
EE9700373A (et) * 1995-06-07 1998-06-15 Astra Aktiebolag Helicobacter pyloriga seotud nukleiinhapete ja aminohapete järjestused diagnoosimiseks ja raviks
EP0971734A4 (en) * 1997-03-26 2001-02-07 Avant Immunotherapeutics Inc CARBOHYDRATE ANTIGENS HAVING IMMUNOLOGICAL REACTIVITY WITH POLYCLONAL ANTISERUMS AGAINST H. PYLORI
CA2289253A1 (en) * 1997-04-30 1998-11-05 Merieux Oravax Anti-helicobacter vaccine composition for use by the subdiaphragmatic systemic route, and combined mucosal/parenteral immunization method
SE9702242D0 (sv) * 1997-06-12 1997-06-12 Astra Ab Vaccine compositions V
SE9702241D0 (sv) * 1997-06-12 1997-06-12 Astra Ab Vaccine compositions IV
US7393529B2 (en) * 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
SE9801288D0 (sv) * 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
JP4346821B2 (ja) * 1998-04-30 2009-10-21 カイロン ソチエタ ア レスポンサビリタ リミタータ H.Pyloriによる感染に対する免疫化および処置
AU3205000A (en) * 1999-02-19 2000-09-04 Astrazeneca Ab Expression of helicobacter polypeptides in pichia pastoris
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
WO2001083531A1 (en) * 2000-04-27 2001-11-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for identifying helicobacter antigens
GB0010371D0 (en) * 2000-04-29 2000-06-14 Astrazeneca Ab Helicobacter pylori antigens
US20020107368A1 (en) * 2000-12-07 2002-08-08 Jing-Hui Tian Helicobacter proteins, gene sequences and uses thereof
WO2005019249A2 (en) 2003-08-15 2005-03-03 University Of Florida Identification of porphyromonas gingivalis virulence polynucleotides for diagnosis, treatment, and monitoring of periodontal diseases
US7381547B2 (en) * 2004-04-28 2008-06-03 Tzam Diagnostics, Llc Methods and compositions to detect bacteria using multiplex PCR
KR100613924B1 (ko) * 2004-06-23 2006-08-21 현대자동차주식회사 자동차 연료 시스템
WO2007014179A2 (en) * 2005-07-25 2007-02-01 University Of Rochester Method for controlling immunodominance
WO2009014782A2 (en) * 2007-04-27 2009-01-29 Dow Global Technologies Inc. Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
CN101496898B (zh) * 2009-02-16 2011-06-15 中国人民解放军军事医学科学院生物工程研究所 一种预防和/或治疗幽门螺杆菌感染的疫苗
RU2449805C1 (ru) 2011-01-27 2012-05-10 Общество С Ограниченной Ответственностью "Гармония" Пептидная фармацевтическая композиция, средство на ее основе для лечения гастродуоденальных заболеваний, вызываемых helicobacter pylori, и способ его использования
US10828358B2 (en) 2015-12-14 2020-11-10 Technische Universität München Helicobacter pylori vaccines
US10577409B2 (en) * 2016-05-26 2020-03-03 Sagabio Co., Ltd. Monoclonal antibody inhibiting immunosuppressive functions of pathogens, antigen-binding fragment thereof, and hybridomas producing such antibody
CN107456578A (zh) * 2016-06-03 2017-12-12 硕英生医股份有限公司 一种关闭病原体的免疫抑制功能的方法及其用途
EP3272354A1 (en) 2016-07-20 2018-01-24 Technische Universität München Agents and methods for the prevention or treatment of h. pylori infections
CN111467368B (zh) * 2020-04-13 2021-05-28 江南大学 含庚糖链的寡糖化合物在制备幽门螺旋杆菌疫苗中的应用
CN113144182B (zh) * 2021-04-22 2023-03-10 成都欧林生物科技股份有限公司 一种幽门螺杆菌口服缓释疫苗及其制备与应用
CN113896775A (zh) * 2021-08-25 2022-01-07 河北医科大学第四医院 幽门螺杆菌特异性免疫原性肽段

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0606921T3 (da) * 1989-03-09 2000-09-04 American Cyanamid Co Fremgangsmåde til isolering af Haemophilus influenzae protein E
US5721349A (en) * 1992-02-26 1998-02-24 Vanderbilt University Vacuolating toxin-deficient H. pylori
MX9301706A (es) * 1992-04-13 1994-05-31 Oravax Inc Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
US5420014A (en) * 1992-04-30 1995-05-30 Auspharm International Ltd. Rapid in vitro test for helicobacter pylori using saliva

Also Published As

Publication number Publication date
IS4615A (is) 1997-11-17
EP0828757A1 (en) 1998-03-18
AU703331B2 (en) 1999-03-25
KR19990022131A (ko) 1999-03-25
CZ357397A3 (cs) 1998-05-13
PL323741A1 (en) 1998-04-14
NO975490D0 (no) 1997-11-28
CA2222797A1 (en) 1996-12-05
WO1996038475A1 (en) 1996-12-05
HUP9901546A2 (hu) 1999-08-30
MX9709194A (es) 1998-07-31
SK155297A3 (en) 1998-08-05
RU2195463C2 (ru) 2002-12-27
IL122340A0 (en) 1998-04-05
BR9608627A (pt) 1999-06-15
EE9700306A (xx) 1998-06-15
US6025164A (en) 2000-02-15
TR199701471T1 (xx) 1998-02-21
AU6020596A (en) 1996-12-18
NO975490L (no) 1998-01-07
NZ303356A (en) 1999-05-28
JPH11507210A (ja) 1999-06-29
HUP9901546A3 (en) 2003-07-28
MY119003A (en) 2005-03-31
CN1191544A (zh) 1998-08-26
TW570925B (en) 2004-01-11
US20020168726A1 (en) 2002-11-14
JP3380559B2 (ja) 2003-02-24

Similar Documents

Publication Publication Date Title
AR003125A1 (es) Antigenos bacterianos para el diagnostico de infecciones con helicobacter pylori, una molecula de adn que lo codifica, un vector, una celula huesped,procedimiento para producir el polipeptido, composiciones para vacunas adecuadas para uso terapeutico y profilactico, el uso del polipeptido en la
CY1121353T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
BR9712852A (pt) Plasmìdeo, composição, processo de imunização de um indivìduo contra um patógeno, vacina recombinante, patógeno vivo atenuado, proteìna bl-1 substancialmente pura, vetor recombinante de expressão, e, anticorpo isolado
BR9712971A (pt) Método para produção de uma vacina para proteção de um hospedeiro contra doença causada com uma cadeia de chlamydia e composição imunológica
BR0210216A (pt) Holotoxina do cólera imunogênica, mutante (ct-crm), composição imunogênica, métodos para aumentar a resposta imune de um hospedeiro vertebrado a um antìgeno, e para produzir uma holotoxina do cólera imunogênica, mutante, sequência ou molécula de ácido nucleico isolado e purificado, célula hospedeira, e, uso de uma holotoxina do cólera mutante
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
FI102382B1 (fi) Ilmentämisjärjestelmä ihmisen respiratory syncytial -viruksen glykoproteiinien immunogeenisia fragmentteja sisältäviä kimeerisiä glykoproteiineja varten
BR9914777A (pt) Moléculas isoladas de ácido nucléico que codificam os fatores induzìveis por células t (tifs), as proteìnas codificadas e os usos das mesmas
AR006999A1 (es) Una composición inmunogénica, terapéutica o profiláctica , que comprende un polipéptido omp106 aislado, un anticuerpo aislado que se liga a dicho polipéptido y una vacuna que lo comprende.
BR9712556A (pt) Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno
BRPI0314373B8 (pt) produto imunogênico estável para a indução de anticorpos contra uma ou várias proteínas antigênicas em um indivíduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico
HK1073064A1 (en) Means for improving immune response
AR004341A1 (es) Vacunas contra tumores y procedimiento para su produccion.
DE69737413D1 (en) Bakterioferritin aus helicobacter pylori
DE69515340T2 (de) Impfstoff gegen mycobakterielle infektionen
DE602004028029D1 (en) Rwendung
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
BR9608894A (pt) Produtos extracelulares abundantes e processos para suas producões e usos
DK1290160T3 (da) Humane Pellino-polypeptider
BR9710849A (pt) Vacina contendo uma peróxi-redoxina e/ou uma beta-tubulina.
SE9604296D0 (sv) New pharmaceutical formulation of polypeptides
ATE283065T1 (de) Mehrzweckvakzine gegen umhüllte viren
MXPA03010527A (es) Composicion de vacuna.
ATE160377T1 (de) Erzeugung von hybrid-genen und proteinen durch rekombination mittels viren
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus